European Atrial Fibrillation Trial "EAFT"


Phase N/A Results

Trial Description

To study the value of anticoagulation in the secondary prevention of stroke in patients with non-rheumatic atrial fibrillation.


  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Warfarin (Coumadin┬«)Drug
    Other Names: Coumadin
    Intervention Desc: Anticoagulant (Vitamin K antagonist)

Trial Design

Randomized, placebo-controlled, international trial of 455 patients at 108 centers.

Patient Involvement

Patients eligible for anticoagulation were randomized to receive either open-label oral anticoagulants or double-blind treatment with aspirin or placebo. Patients ineligible for anticoagulation, based on unwillingness of physician or patient, were randomized to receive either double-blind treatment with aspirin (300mg) or matching placebo. Physicians were allowed to choose the type of oral anticoagulant but treatment was adjusted to International Normalized Ratios (INR) or 2.5-4.0.


Type Measure Time Frame Safety Issue
Primary Vascular death, nonfatal stroke, nonfatal myocardial infarction or systemic embolism assessed every 4 months.
Secondary Death from all causes, non-fatal or fatal stroke of any cause, major thromboembolic events.


Netherlands Heart Foundation, Bayer Germany and Bayer subsidiaries in participating countries, UK Stroke Association, University Hospitals of Utrecht and Rotterdam.